fbpx Skip to main content

Member's Profile

ALX Oncology

323 Allerton Avenue
South San Francisco,   California
United States
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About ALX Oncology
Biotech Company
ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.
Related News
No related news posted by this Member